We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Cigna
CI
$77B
| $8.96M | 0.06% |
37,794
-57,279
| -60% | -$14.3M |
|
302
IDEX
IEX
$16.6B
| $8.83M | 0.06% |
40,134
+31,397
| +359% | +$6.94M |
|
303
Charter Communications
CHTR
$15.7B
| $8.73M | 0.06% |
12,108
-9,953
| -45% | -$6.7M |
|
304
American Express
AXP
$229B
| $8.71M | 0.06% |
52,729
-37,433
| -42% | -$5.86M |
|
305
Waters Corp
WAT
$36.4B
| $8.68M | 0.06% |
25,112
+18,988
| +310% | +$6.01M |
|
|
EPIX
306
DELISTED
ESSA Pharma
EPIX
| $8.59M | 0.06% |
300,525
+300,508
| +1,767,694% | +$8.74M |
|
307
NeoGenomics
NEO
$1.71B
| $8.46M | 0.06% |
187,332
-109,187
| -37% | -$4.84M |
|
308
Okta
OKTA
$23.9B
| $8.26M | 0.06% |
33,765
+11,789
| +54% | +$2.85M |
|
309
CSX Corp
CSX
$96B
| $8.26M | 0.06% |
257,349
+83,310
| +48% | +$2.75M |
|
|
VRAY
310
DELISTED
ViewRay, Inc.
VRAY
| $8.18M | 0.06% |
1,239,892
+378,930
| +44% | +$2.02M |
|
311
MetLife
MET
$61.2B
| $8.18M | 0.06% |
136,688
-174,441
| -56% | -$11.1M |
|
312
Marriott International
MAR
$101B
| $8.15M | 0.06% |
59,667
+38,838
| +186% | +$5.6M |
|
313
Personalis
PSNL
$1.28B
| $8.14M | 0.06% |
321,867
+110,551
| +52% | +$2.53M |
|
314
Hasbro
HAS
$12.8B
| $8.09M | 0.06% |
85,582
-11,145
| -12% | -$1.07M |
|
315
Axsome Therapeutics
AXSM
$12.3B
| $8M | 0.05% |
118,602
+2,800
| +2% | +$168K |
|
316
Newmont
NEM
$98.5B
| $7.95M | 0.05% |
125,397
-81,804
| -39% | -$5.48M |
|
317
Neurocrine Biosciences
NBIX
$17.7B
| $7.93M | 0.05% |
81,493
-80,376
| -50% | -$7.7M |
|
318
Precision BioSciences
DTIL
$187M
| $7.93M | 0.05% |
+21,105
| New | +$6.34M |
|
319
DaVita
DVA
$15.2B
| $7.92M | 0.05% |
65,777
+25,160
| +62% | +$2.98M |
|
|
SAGE
320
DELISTED
Sage Therapeutics
SAGE
| $7.87M | 0.05% |
138,568
-6,079
| -4% | -$430K |
|
321
Healthpeak Properties
DOC
$15.5B
| $7.8M | 0.05% |
234,461
+190,101
| +429% | +$6.38M |
|
322
Louisiana-Pacific
LPX
$5.19B
| $7.76M | 0.05% |
+128,748
| New | +$8.23M |
|
323
Jack Henry & Associates
JKHY
$10.9B
| $7.7M | 0.05% |
47,084
+42,727
| +981% | +$6.83M |
|
|
KYNB
324
Kyntra Bio
KYNB
$28.5M
| $7.68M | 0.05% |
11,539
+4,154
| +56% | +$2.39M |
|
|
TRIL
325
DELISTED
Trillium Therapeutics Inc.
TRIL
| $7.66M | 0.05% |
790,098
+790,056
| +1,881,086% | +$7.44M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.